CClinicalTrials.gg
Sign In
RecruitingNCT07142044STEPUpdated Jul 10, 2026

Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study)

A Phase 1/2 interventional study of EC5026 oral tablet and Placebo in Parkinson's Disease (PD), sponsored by EicOsis Human Health Inc.. Recruiting at 1 site in United States. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by EicOsis Human Health Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.
Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if the oral drug candidate EC5026 is safe and targets the correct pathways to treat Parkinson's Disease in adults. It will also learn about the levels of drug that are achieved in blood and in the fluid surrounding the brain (spinal fluid). The main questions it aims to answer are:

  • Is EC5026 safe in adults with Parkinson's Disease?
  • What are the levels of EC5026 achieved after oral administration for 28 days?
  • What molecules or pathways does EC5026 target, and to what extent?

In addition, although it is not one of the primary aims of the study, this clinical trial will also explore if oral administration of EC5026 improves the symptoms of Parkinson's Disease.

Researchers will compare EC5026 to a placebo (a look-alike substance that contains no drug).

Participants will:

  • Take EC5026 or a placebo every day for 28 consecutive days
  • Visit the clinic for frequent checkups, blood tests, spinal fluid tests, and questionnaires
Read the detailed description

This is a double-blind, randomized, placebo-controlled Phase 1b multiple ascending dose (MAD) study to be conducted in adult male and female participants with Parkinson's Disease. The aim is to evaluate the safety, pharmacokinetics (PK), target engagement, and exploratory efficacy, of 2 ascending dose regimens of oral EC5026 in participants with Parkinson's Disease.

The study drug, EC5026, is an orally bioavailable inhibitor of an enzyme, soluble epoxide hydrolase (sEH), that is being developed as a first-in-class anti-inflammatory agent. Inhibiting sEH maintains concentrations of bioavailable polyunsaturated fatty acid epoxides, known as epoxy fatty acids (EpFAs). EpFAs are potent, endogenous fatty acids that are highly produced in areas of damaged and inflamed tissue but are rapidly metabolized by sEH in vivo. Therefore, selective inhibition of sEH prolongs and enhances the anti-inflammatory activity of EpFAs. Several studies have identified the sEH enzyme as a potential therapeutic target for modulating neuroinflammatory responses in PD.

02

Conditions studied

  • Parkinson's Disease (PD)

Keywords

  • EC5026
  • Parkinson's Disease
  • Soluble Epoxide Hydrolase
  • sEH
  • Soluble Epoxide Hydrolase inhibitor
03

In context

Lead sponsor

EicOsis Human Health Inc. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Adult males and females, 50 to 80 years of age (inclusive) at the time of Screening.
  2. Able to understand the consent form, and to provide voluntary written informed consent.
  3. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study-related procedures to complete the study.
  4. Confirmed diagnosis of idiopathic Parkinson's Disease according to 2015 Movement Disorder Society (MDS) clinical diagnostic criteria.
  5. Off state Hoehn \& Yahr below Stage 3 at the time of Screening.
  6. Participants must be on stable doses of L-dopa with or without other adjunctive PD therapy for at least 30 days prior to enrollment. Doses should be expected to remain stable for the duration of the study.
  7. Participants must be in overall stable condition, as determined by pre-study medical history, physical examination, clinical laboratory tests, and 12 lead ECG measurements.
  8. Participants must have normal or not clinically significant clinical laboratory test results, as determined by the study investigator, including coagulation panel, blood cell counts, comprehensive metabolic panel analytes, and creatinine clearance (60 cm3/min or greater). Clinical laboratory tests results that are consistent with known, stable comorbidities will be allowed as long as the comorbidities do not represent an exclusion criteria per se.
  9. Participants must have a negative urinary drug screen (UDS) for illicit drugs and a negative alcohol breath test.
  10. Abstention from use of other investigative or non-approved drugs for the duration of the trial
  11. Male participants who are not surgically sterile (vasectomized) and their female sexual partners must agree to use contraception during the study period and for 2 months after receiving the last dose of study drug.
  12. Male participants must not donate sperm during the study and for 12 months after receiving the last dose of study drug.
  13. Female participants must be non-pregnant, non-lactating, and either postmenopausal for at least 1 year, or surgically sterile (bilateral tubal ligation, 'clipping or tying tubes,' or hysterectomy) for at least 3 months, or they must agree to use two forms of highly effective contraception method (less than 1 pregnancy per 100 people using the method for one year) from 28 days and/or their last confirmed menstrual period prior to study enrollment (whichever is longer) until 2 months after receiving the last dose of study drug. Postmenopausal status will be defined as follows: minimum 1 year; amenorrhea duration of 12 consecutive months and a serum FSH value >40 IU/L; postmenopausal status must be confirmed by an FSH test at Screening). Highly effective contraception methods include: Intra-uterine device (IUD) containing either copper or levonorgestrel (e.g., Mirena®), and/or barrier methods of contraception, including condoms (external or internal) and diaphragm ('cap'). Hormonal methods of contraception (with the exception of hormonal IUD) are not permitted within this study. Female participants will refrain from using hormonal contraceptives for at least 28 days prior to study entry until the end of the study period. Participants/Participant's partner(s) must also use a barrier form of contraception, from the first dose of study drug through until 2 months after the last dose. For all females of childbearing potential, the pregnancy test result must be negative at Screening and Pre-Study Baseline (Day -1).
  14. Participants must be able to speak, read, and understand English sufficiently to allow comprehension and completion of all study assessments.

Exclusion criteria

Exclusion Criteria:

  1. Atypical parkinsonian syndrome or secondary parkinsonism (e.g., due to drugs or toxins, metabolic neurogenetic disorders, encephalitis, cerebrovascular disease or non-PD degenerative disease).
  2. Family history of early onset PD (age \<50 years) or known personal genetically causal etiology of PD.
  3. Diagnosis of any other clinically significant neurologic disease that may confound the assessment of the study drug on PD symptoms
  4. Not stabilized with current therapeutic regimen for PD or likely to require changes in L-dopa therapy over the duration of the trial.
  5. Presence of PD psychosis or dementia, or other neuropsychiatric or psychiatric conditions impeding informed consent or compliance with study interventions.
  6. Severe dyskinesia (defined as per MDS-UPDRS) during a "normal day" that would significantly interfere with the participant's ability to perform study assessments.
  7. History of neurosurgery for PD or tremor.
  8. Clinically significant medical, surgical, or laboratory abnormalities in the judgement of the Investigator.
  9. Participants with any clinically unstable or significant cardiovascular (including acute coronary syndrome within the prior year to Screening), renal, hepatic, respiratory, gastrointestinal, hematological, endocrine, or infectious disease (including HIV infection).
  10. Participants with clinically significant abnormalities on screening vital signs, laboratory tests, and/or ECG, per investigator's judgement. Participants with poor venous access will also be excluded.
  11. Participants with a family history of significant cardiac disease (i.e., sudden death in first degree relative; myocardial infarction before the age of 50).
  12. Participants with a history of disorders of the hypothalamic-pituitary-adrenal axis, including adrenal insufficiency and Cushing's, or with a history of disorders of the hypothalamic-pituitary-gonadal axis, including hypogonadism.

  13. Participants with any of the following blood values at screening:

    • Abnormal plasma renin and/or aldosterone value
    • Morning cortisol level \<5 mcg/dL
    • ACTH stimulated cortisol levels \<18 mcg/dL at 60 minutes after ACTH injection at screening, or
    • Abnormal FSH, LH, testosterone (for males), or estradiol (for females, unless post-menopausal)
  14. Participants who have used any topical, oral, or intravenous exogenous corticosteroids within 12 weeks and/or intra-articular exogenous corticosteroids within 6 months prior to the start of the trial, or who plan on using them during the study.
  15. Participants who have used chemotherapy agents, or who have a personal history of cancer or cancer in first degree relatives suggestive of elevated cancer risk, other than nonmetastatic skin cancer that has been completely excised, within 5 years prior to Screening.
  16. Participants who have used (within 14 days of randomization) or plan on using during the duration of the study any prescription or over-the-counter drugs that are moderate or strong CYP3A4 inducers or inhibitors.
  17. Participants who have used (within 14 days of randomization) or plan on using during the duration of the study any dietary aids, supplements, or foods that are moderate or strong CYP3A4 inhibitors (e.g., grapefruit juice).
  18. Participants with difficulty in swallowing oral medications
  19. Participants who have used any other investigational drug within 1 month or 5 half-lives, whichever is longer, prior to enrollment.
  20. Participants with a documented history of difficult lumbar puncture procedures, to the investigator's discretion.
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    EC5026 2 mg daily

    Once-daily, oral dose of 2 mg of EC5026 for 28 consecutive days

    Drug: EC5026 oral tablet

  • Experimental
    EC5026 4 mg daily

    Once-daily, oral dose of 4 mg of EC5026 for 28 consecutive days

    Drug: EC5026 oral tablet

  • Placebo comparator
    Placebo

    Once-daily, matching placebo for each dose cohort, orally for 28 consecutive days.

    Drug: Placebo

Interventions

  • DrugEC5026 oral tablet

    Oral soluble epoxide hydrolase inhibitor

  • DrugPlacebo

    Matching oral placebo

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAE) [Safety and Tolerability]

    All AEs reported or observed during the study will be recorded on the electronic case report forms (eCRF). Information to be collected includes drug treatment, type of event, time of onset, dosage, investigator-specified assessment of severity and relationship to study drug, time of resolution of the event, seriousness, any required treatment or evaluations, and outcome. Any AEs resulting from concurrent illnesses, reactions to concurrent illnesses, reactions to concurrent medications, or progression of disease states must also be reported. All AEs will be followed until they are resolved, stable, or judged by the investigator to be not clinically significant. The Medical Dictionary for Regulatory Activities will be used to code all AEs.

    Time frame: 56 days

Other outcomes

  1. Effects of 2 ascending multiple dose regimens of EC5026 versus placebo on plasma and cerebrospinal fluid levels of EC5026

    Standard validated EC5026 measurement platform will be used

    Time frame: 56 days

  2. Effects of 2 ascending multiple dose regimens of EC5026 versus placebo on plasma and cerebrospinal fluid target engagement biomarkers.

    Target engagement biomarkers will include changes from baseline of a validated analytical platform of inflammatory cytokines, neurological markers including target inflammatory genes tied to the mechanism of action, ER-stress response genes, and Parkinson's Disease specific biomarkers (including alpha-synuclein, Abeta42, pTau-181, GFAP, and Neurofilament Light).

    Time frame: 56 days.

  3. Change from Baseline in Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Score (Day 14)

    Change from Baseline in Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Score on Day 14. The Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) is a comprehensive tool used to assess Parkinson's Disease (PD) symptoms and severity through a series of questions rated by clinicians, patients, and caregivers. Scores are on a 0-4 scale, with higher scores indicating a greater impact of PD symptoms. The scale is divided into four parts, covering non-motor and motor experiences of daily living, motor examination, and motor complications.

    Time frame: Day 14

  4. Change from Baseline in Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Score (Day 28)

    Change from Baseline in Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Score on Day 28. The Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) is a comprehensive tool used to assess Parkinson's Disease (PD) symptoms and severity through a series of questions rated by clinicians, patients, and caregivers. Scores are on a 0-4 scale, with higher scores indicating a greater impact of PD symptoms. The scale is divided into four parts, covering non-motor and motor experiences of daily living, motor examination, and motor complications.

    Time frame: Day 28

  5. Change from Baseline in Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Score (Day 56 - End of Study)

    Change from Baseline in Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Score on Day 56 or end of study visit. The Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) is a comprehensive tool used to assess Parkinson's Disease (PD) symptoms and severity through a series of questions rated by clinicians, patients, and caregivers. Scores are on a 0-4 scale, with higher scores indicating a greater impact of PD symptoms. The scale is divided into four parts, covering non-motor and motor experiences of daily living, motor examination, and motor complications.

    Time frame: Day 56

  6. Change from Baseline in Movement Disorders Society Non-Motor Symptom Scale (NMS) (Day 14)

    Change from Baseline in Movement Disorders Society Non-Motor Symptom Scale (NMS) on Day 14. The Movement Disorders Society (MDS) Non-Motor Symptom Scale (MDS-NMS) is evaluates 52 items, grouped according to clinical content into 13 domains. Items are scored for frequency (from 0 \[never\] to 4 \[majority of time\]) and severity (from 0 \[not present\] to 4 \[severe\]), which are multiplied to generate the item total score. Scores for each domain and the total rating scale (maximum, 832 points) are calculated by summing the corresponding items. The scale provides a total score representing the non-motor burden. Higher scores imply a higher non-motor symptom burden.

    Time frame: Day 14

  7. Change from Baseline in Movement Disorders Society Non-Motor Symptom Scale (NMS) (Day 28)

    Change from Baseline in Movement Disorders Society Non-Motor Symptom Scale (NMS) on Day 28. The Movement Disorders Society (MDS) Non-Motor Symptom Scale (MDS-NMS) is evaluates 52 items, grouped according to clinical content into 13 domains. Items are scored for frequency (from 0 \[never\] to 4 \[majority of time\]) and severity (from 0 \[not present\] to 4 \[severe\]), which are multiplied to generate the item total score. Scores for each domain and the total rating scale (maximum, 832 points) are calculated by summing the corresponding items. The scale provides a total score representing the non-motor burden. Higher scores imply a higher non-motor symptom burden.

    Time frame: Day 28

  8. Change from Baseline in Movement Disorders Society Non-Motor Symptom Scale (NMS) (Day 56 - End of Study)

    Change from Baseline in Movement Disorders Society Non-Motor Symptom Scale (NMS) on Day 56 or end of study visit. The Movement Disorders Society (MDS) Non-Motor Symptom Scale (MDS-NMS) is evaluates 52 items, grouped according to clinical content into 13 domains. Items are scored for frequency (from 0 \[never\] to 4 \[majority of time\]) and severity (from 0 \[not present\] to 4 \[severe\]), which are multiplied to generate the item total score. Scores for each domain and the total rating scale (maximum, 832 points) are calculated by summing the corresponding items. The scale provides a total score representing the non-motor burden. Higher scores imply a higher non-motor symptom burden.

    Time frame: Day 56

  9. Change from Baseline in Time to Complete Time Up and Go (TUG) Test (Day 14)

    Change from Baseline in Time to Complete Time Up and Go (TUG) Test on Day 14. The Time Up and Go (TUG) test time varies, but healthy older adults typically complete it in under 10 seconds. A score of 12 seconds or more indicates increased fall risk, with a threshold of 13.5 seconds often used for community-dwelling adults. Scores of 20 seconds or more signal poor physical performance and higher fall risk, while very frail individuals might take two minutes or more to finish.

    Time frame: Day 14

  10. Change from Baseline in Time to Complete Time Up and Go (TUG) Test (Day 28)

    Change from Baseline in Time to Complete Time Up and Go (TUG) Test on Day 28. The Time Up and Go (TUG) test time varies, but healthy older adults typically complete it in under 10 seconds. A score of 12 seconds or more indicates increased fall risk, with a threshold of 13.5 seconds often used for community-dwelling adults. Scores of 20 seconds or more signal poor physical performance and higher fall risk, while very frail individuals might take two minutes or more to finish.

    Time frame: Day 28

  11. Change from Baseline in Time to Complete Time Up and Go (TUG) Test (Day 56 - End of Study)

    Change from Baseline in Time to Complete Time Up and Go (TUG) Test on Day 56 or end of study visit. The Time Up and Go (TUG) test time varies, but healthy older adults typically complete it in under 10 seconds. A score of 12 seconds or more indicates increased fall risk, with a threshold of 13.5 seconds often used for community-dwelling adults. Scores of 20 seconds or more signal poor physical performance and higher fall risk, while very frail individuals might take two minutes or more to finish.

    Time frame: Day 56

  12. Change from Baseline in Clinical Global Impression (CGI) Scale (Day 14)

    Change from Baseline in Clinical Global Impression (CGI) Scale on Day 14. The CGI was developed for use in NIMH-sponsored clinical trials to provide a brief, stand-alone assessment of the clinician's view of the patient's global functioning prior to and after initiating a study medication. The CGI has two components-the CGI-Severity, which rates illness severity (on a scale from 1 to 7), and the CGI-Improvement, which rates change from the initiation (baseline) of treatment (on a similar 7-point scale). Higher scores in the 7-point scale for each of the components implies worse severity (CGI-S) or a change to worse from baseline (CGI-I).

    Time frame: Day 14

  13. Change from Baseline in Clinical Global Impression (CGI) Scale (Day 28)

    Change from Baseline in Clinical Global Impression (CGI) Scale on Day 28. The CGI was developed for use in NIMH-sponsored clinical trials to provide a brief, stand-alone assessment of the clinician's view of the patient's global functioning prior to and after initiating a study medication. The CGI has two components-the CGI-Severity, which rates illness severity (on a scale from 1 to 7), and the CGI-Improvement, which rates change from the initiation (baseline) of treatment (on a similar 7-point scale). Higher scores in the 7-point scale for each of the components implies worse severity (CGI-S) or a change to worse from baseline (CGI-I).

    Time frame: Day 28

  14. Change from Baseline in Clinical Global Impression (CGI) Scale (Day 56 - End of Study)

    Change from Baseline in Clinical Global Impression (CGI) Scale on Day 56. The CGI was developed for use in NIMH-sponsored clinical trials to provide a brief, stand-alone assessment of the clinician's view of the patient's global functioning prior to and after initiating a study medication. The CGI has two components-the CGI-Severity, which rates illness severity (on a scale from 1 to 7), and the CGI-Improvement, which rates change from the initiation (baseline) of treatment (on a similar 7-point scale). Higher scores in the 7-point scale for each of the components implies worse severity (CGI-S) or a change to worse from baseline (CGI-I).

    Time frame: Day 56

  15. Change from Baseline in Parkinson's Disease Questionnaire (PDQ-39) total score (Day 14)

    Change from Baseline in Parkinson's Disease Questionnaire (PDQ-39) total score on Day 14. The PDQ-39 is a 39-item self-report questionnaire, which assesses Parkinson's disease-specific health related quality over the last month. Specifically, it assesses how often patients experience difficulties across the 8 quality of life dimensions of functioning and well-being. It uses a 5-point scale for each of the 39 questions as follows: 0 = Never; 1 = Rarely; 2 = Sometimes; 3 = Often; and 4 = Always. The minimum score is 0 that means good health, while the maximum score is 100 that is bad health; a higher score indicates a lower quality of life.

    Time frame: Day 14

  16. Change from Baseline in Parkinson's Disease Questionnaire (PDQ-39) total score (Day 28)

    Change from Baseline in Parkinson's Disease Questionnaire (PDQ-39) total score on Day 28. The PDQ-39 is a 39-item self-report questionnaire, which assesses Parkinson's disease-specific health related quality over the last month. Specifically, it assesses how often patients experience difficulties across the 8 quality of life dimensions of functioning and well-being. It uses a 5-point scale for each of the 39 questions as follows: 0 = Never; 1 = Rarely; 2 = Sometimes; 3 = Often; and 4 = Always. The minimum score is 0 that means good health, while the maximum score is 100 that is bad health; a higher score indicates a lower quality of life.

    Time frame: Day 28

  17. Change from Baseline in Parkinson's Disease Questionnaire (PDQ-39) total score (Day 56 - End of Study)

    Change from Baseline in Parkinson's Disease Questionnaire (PDQ-39) total score on Day 56. The PDQ-39 is a 39-item self-report questionnaire, which assesses Parkinson's disease-specific health related quality over the last month. Specifically, it assesses how often patients experience difficulties across the 8 quality of life dimensions of functioning and well-being. It uses a 5-point scale for each of the 39 questions as follows: 0 = Never; 1 = Rarely; 2 = Sometimes; 3 = Often; and 4 = Always. The minimum score is 0 that means good health, while the maximum score is 100 that is bad health; a higher score indicates a lower quality of life.

    Time frame: Day 56

07

Study locations

1 of 1 sites recruiting
  • University of California Davis
    Sacramento, California 95817, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07142044
Lead sponsor
EicOsis Human Health Inc.
Collaborators
University of California, Davis, Michael J. Fox Foundation for Parkinson's Research
Responsible party
Sponsor
First posted
Aug 26, 2025
Start date
Nov 1, 2025
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jul 10, 2026

Study contacts

William K Schmidt, PhD
Contact
wkschmidt@eicosis.com
650-438-3018
William K Schmidt, PhD
study director · EicOsis Human Health Inc.
Lin Zhang, MD, PhD
principal investigator · UC Davis Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

EicOsis Human Health Inc.

Start the discussion